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Background: Prevention and optimal management of
hypertension in the general population is paramount to
the achievement of the World Heart Federation (WHF)
goal of reducing premature cardiovascular disease
(CVD) mortality by 25% by the year 2025 and
widespread access to good quality antihypertensive
medicines is a critical component for achieving the
goal. Despite research and evidence relating to other
medicines such as antimalarials and antibiotics, there
is very little known about the quality of generic
antihypertensive medicines in low-income and middle-
income countries. The aim of this study was to
determine the physicochemical equivalence
(percentage of active pharmaceutical ingredient, API)
of generic antihypertensive medicines available in the
retail market of a developing country.
Methods: An observational design will be adopted,
which includes literature search, landscape
assessment, collection and analysis of medicine
samples. To determine physicochemical equivalence, a
multistage sampling process will be used, including (1)
identification of the 2 most commonly prescribed
classes of antihypertensive medicines prescribed in
Nigeria; (2) identification of a random sample of 10
generics from within each of the 2 most commonly
prescribed classes; (3) a geographical representative
sampling process to identify a random sample of 24
retail outlets in Nigeria; (4) representative sample
purchasing, processing to assess the quality of
medicines, storage and transport; and (5) assessment
of the physical and chemical equivalence of the
collected samples compared to the API in the relevant
class. In total, 20 samples from each of 24 pharmacies
will be tested (total of 480 samples).
Discussion: Availability of and access to quality
antihypertensive medicines globally is therefore a vital
strategy needed to achieve the WHF 25×25 targets.
However, there is currently a scarcity of knowledge
about the quality of antihypertensive medicines
available in developing countries. Such information is
important for enforcing and for ensuring the quality of
antihypertensive medicines.
BACKGROUND
Elevated blood pressure (BP), often termed
hypertension, is one of the most important
public health problems worldwide affecting 1
billion people, three-quarters of which live in
the low-income and middle-income countries.1
High BP is also the leading cause of cardiovas-
cular disease (CVD) and is responsible for
13% of deaths globally.2 Indeed, high BP is
second, after smoking, as a contributor to the
global burden of disease in the most recent
analysis.3 In most individuals, adequate man-
agement and control of BP is associated with a
reduction in deaths and disability from a
number of conditions, including cerebrovascu-
lar, cardiovascular and renal disease.4
Therefore, prevention and optimal manage-
ment of high BP in the general population is
paramount to the achievement of the World
Heart Federation (WHF) goal of reducing pre-
mature CVD mortality by 25% by the year
2025 and widespread access to good quality
antihypertensive medicines is a critical compo-
nent for achieving the goal.5
Summary Box
▸ This protocol outlines an observational study
that includes identification, assessment, collec-
tion and analysis of medicine samples.
▸ Availability of and access to quality antihyperten-
sive medicines globally is a vital strategy needed
to achieve the World Heart Federation 25×25
target.
▸ This research will inform evidence about the
quality of antihypertensive medicines available in
a developing country.
▸ This evidence will directly inform decision-
makers about the potential need for implementa-
tion of mechanisms to ensure availability of
quality medicines to those who need it.
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In recent years, it has emerged that the availability of
substandard medicines is widespread and is a crucial
public health problem in developing countries. In these
countries, half of the medicines for major diseases such
as malaria have been found to be substandard in quality
and often have little or no active ingredient.6
Substandard medicines are deﬁned as medicines that are
produced with inadequate attention to good manufactur-
ing practices and may have contents or dissolution times
that are outside the pharmacopoeia accepted limits.6–10
The problem of modern-day substandard medicines was
ﬁrst highlighted in 1985, and according to WHO, 25% of
all medicines available in developing countries are sub-
standard.11 Substandard generic medicines are a major
contributor and have been shown to constitute 40–50%
of all medicine supplies in Nigeria,12 one-third of all anti-
biotics and antimalarial medicines in Nigeria and
Thailand, and 9% of medicines in India.13 Substandard
generic medicines share a huge market as estimated by
WHO at more than US$35 billion which represents >15%
of the pharmaceutical market worldwide.14
Almost all kinds of medicines can be substandard;
however, most existing studies have investigated antimalar-
ial medicines and antibiotics. The US Pharmacopoeia
(USP) drug quality and information programme listed
antihypertensive medicines among a class of possible sub-
standard medicines in the African region.14 A study carried
out in Philippines found that the antihypertensive medi-
cine Adalat (Nifedipine) was one of the top ﬁve substand-
ard medications.15 However, there is currently very little
research being performed to assess the quality of generic
antihypertensive medicines. Importantly, given that people
with high BP often require lifelong adherence to indicated
medicines, the problem of substandard antihypertensive
medicines is potentially a serious public health issue.
Therefore, the aim of this pilot study was to determine the
physicochemical equivalence (percentage of active
pharmaceutical ingredient (API)) of generic antihyperten-
sive medicines available in the retail market of Nigeria.
METHODS/DESIGN
An observational study design will be adopted, which
includes searching publically available data relating to
antihypertensive medicines in Nigeria as well as collec-
tion and laboratory analysis of medicine samples.
Technical aspects of the methodology are based on inte-
grated recommendations from published guidelines and
recommendations.16 17 To determine physicochemical
equivalence, a multistage sampling process will be used,
including (1) identiﬁcation of the two most commonly
prescribed classes of antihypertensive medicines pre-
scribed in Nigeria; (2) identiﬁcation of a random
sample of 10 generic medicines from within each of the
two most commonly prescribed classes; (3) a geograph-
ical sampling process to identify a random sample of 24
retail outlets in Nigeria; (4) sample purchasing, process-
ing, storage and transport; and (5) assessment of the
physical and chemical equivalence of the collected
samples compared to the active drug in the relevant
class.
Context
Nigeria was chosen as the country in which medicines
will be collected for this study. Nigeria is a developing
country with a large population with previously demon-
strated availability of substandard antimalarial medi-
cines.18 The prevalence of hypertension in Nigeria is
currently estimated to be 28.9% and this contributes a
substantial proportion of the total burden in Africa due
to the large population of the country which is currently
estimated to be over 170 million.19 This increasing
burden is increasing the need for government and other
health policy planners to ensure the availability of high-
quality evidence-based medicines for hypertension.20
Nigeria has an area of 923 768 km2 (about 574 000
square miles).21 It is the most densely populated country
in Africa and represents about 20% of the total popula-
tion of sub-Saharan Africa.21 Although Nigeria has a
large number of ethnic groups (∼250), the three most
populous are the Hausas in the North, Yorubas in the
West and Ibos in the Eastern part of Nigeria. Nigeria has
a total of 36 states and 774 local government areas
(LGAs) that are subordinate to the relevant states and
the Federal Capital Territory. According to the WHO,
over half a million Nigerians died from non-
communicable diseases, including CVDs, in 2012 and
that 35% of Nigerian adults had elevated BP in 2008.22
Other population-based research reports that the preva-
lence of hypertension in Nigeria is around 23% of the
adult population with rates being higher in urban than
in rural dwellers (32.7% and 12.9%).23 For this study, we
have purposively selected a state from three geopolitical
zones.
Identification of antihypertensive classes for collection
To identify which generic brands to include for sam-
pling, we initially identiﬁed the most commonly pre-
scribed brand and antihypertensive for each of the ﬁve
primary classes of antihypertensive medicines available
in Nigeria (table 1). The major classes identiﬁed were
(calcium channel blockers, β blockers, ACE inhibitors,
angiotensin receptor blockers and centrally acting
drugs) based on information obtained from local
opinion leaders and from publically available informa-
tion via the National Agency Food and Drug
Administration and Control (NAFDAC) agency.24 Based
on the classes and brands identiﬁed (listed in table 1), a
detailed and comprehensive list of all the available
generic brands was prepared based on data publically
available through NAFDAC.24 It was decided that the
project would focus on the two most commonly pre-
scribed antihypertensive classes and these were amlodi-
pine and lisinopril. A computerised random sequence
was then used to randomly select 10 generic brands of
amlodipine and lisinopril. These 20 generic medicines
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are available in Nigeria and will form the basis of the
samples for collection.
Geographical sampling framework
A stepwise and semi-random sampling framework was
developed to determine which retail outlets would even-
tually be included in the study. The purpose and
concept behind the sampling framework is to identify a
combination of urban and rural locations in northern
and southern states of Nigeria via a stratiﬁed yet random
and systematic approach. The steps involved in the sam-
pling framework are as follows:
1. Identiﬁcation of three states representing varied geo-
political areas through consultation with local experts
(purposive sample).
2. For each of the three states, we will then obtain a list
of LGAs from which we will randomly select one
rural and one urban LGA. Therefore, across the
three states, a total of six LGA will be included for
sampling (three rural and three urban).
3. It was not feasible to source a list of all pharmacies in
each of the LGA, so we will use geographical
mapping software (QGIS Geographic Information
System, V.2.8.3-Wien, 2015) to randomly select four
geographical coordinates in each of the selected
LGAs.
4. The nearest available pharmacy outlet to each of the
geographical coordinates will then be identiﬁed by
the research assistant who will act as a mystery
shopper and purchase the predetermined generic
medicines from each shop. The total sample will
therefore include 24 retail outlets (pharmacy shops)
from six LGAs across three states in different geopol-
itical zones of Nigeria.
Medicine purchasing, processing storage and transport
Once the ﬁnal list of 24 retail outlets is conﬁrmed, a
research assistant will act as a mystery shopper (a hired
research assistant who speaks the local language) who
will visit the identiﬁed outlet and systematically
purchased all the available and preselected generic
brands for each of the chosen antihypertensive medi-
cines. The covert approach is to minimise the risk that a
seller might realise they are to be a part of a research
project and therefore raise suspicion and minimise the
risk that the seller declines to sell the required samples.
Trained research assistants within our existing networks
will collect the medicine samples from the pharmacies
and will also record the exact geographical coordinates
of the pharmacy. Researchers will pose as clients to buy
the 20 samples from each of the 24 pharmacy shops
(total of 480 samples). A full box (usually 28 or 30
tablets) for each generic medicine will be purchased so
the number of dosage units in a box will be the number
purchased.
Once purchased, each sample will be retained in their
point-of-purchase packaging and placed in an individual
zip-lock bag together with a completed standardised
data collection form. The data collection form for each
sample will include recording of the outlet type, date of
purchase, price paid, brand name, formulation, batch
number, manufacturer, number of tablets per sample
and expiry date. Samples will then be safely and securely
stored in an air-conditioned room (∼20°C) in a central
location at one of our researcher’s sites, pending dis-
patch. As such, efforts will be made to ensure that the
medicines are not degraded by inadequate storage con-
ditions, which could confound the ﬁndings. As soon as
all samples have been collected, they will be dispatched,
via international courier (eg, DHL Express), to the
London School of Hygiene and Tropical Medicine
(LSHTM) in London, UK for further processing and
chemical content analysis.
Sample processing and laboratory analyses
For every sample under investigation, a digital photo-
graph of the packaging and contents of each sample will
be taken. Sample information (including name, stated
active ingredients, dose form, outlet, district, date of pur-
chase, manufacturer, NAFDAC registration number,
batch number, expiry date, number of tablets per packet
and price paid) will be compared to the data collected
for each sample during the ﬁeldwork collection and
logged on an excel sheet. The integrity of the pack-
aging, the features of the blister pack with indented or
printed batch number, and dates of manufacture and
expiry, as well as the appearance of tablets, form the ﬁrst
steps in determining the quality of the product.
Included on the package should be the list of active
ingredients, name and address of the manufacturer,
storage conditions, batch or lot number, date of manu-
facture and directions for use. Enclosed with the tablets
should be an instruction leaﬂet in the appropriate lan-
guage without any spelling errors. All tablets will then be
weighed, and their dimensions, colour and physical
appearance characteristics (such as any cracks, logos and
chips) recorded prior to laboratory analysis.
Table 1 Most commonly prescribed antihypertensive











β blockers Atenolol 52





*Based on data available on the NAFDAC website http://www.
nafdac.gov.ng and information obtained from local experts.
ARB, angiotensin receptor blocker; NAFDAC, National Agency Food
and Drug Administration and Control.
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Chemical content analysis
Quantitative analysis will be conducted at the LSHTM to
measure the amount of stated API in the tablets using
high-performance liquid chromatography (HPLC). We
will use the published methods in the USP monographs
for the analysis of tablets of amlodipine besylate and
those of lisinopril.25 26 Tablets will be dissolved in a
solvent, sonicated and centrifuged. The supernatant will
then be injected into the HPLC column and the
amount of API present in each tablet will be determined
and expressed as percentage found. We will also consult
USP monographs for the two antihypertensive medicines
to see what the tolerance rules stipulate which is gener-
ally considered acceptable quality if the API measured is
90–110% for amlodipine besylate tablets and 98–102%
for lisinopril tablets.
Sample size and analysis
Laboratory data will be combined with sample data and
analysed using STATA (Stata/IC). Descriptive statistics
will be used to compare the generic medicines on their
physical and chemical characteristics with the reference
product (medicine). In addition, we will compare
equivalence in rural versus urban areas. Proportions will
be evaluated using χ2 tests and associations between
poor quality and high-quality antihypertensive medicines
will be explored. The USP recommends 30 dosage units
for a single tablet/capsule medicine of the same lot
number from each location. Such a sample size gives
enough dosage units to determine identity and accurate
estimates of content of active ingredients.
Ethics approvals
The study will seek ethical approval from the LSHTM
Ethics Committee and the relevant Nigerian state-based
ethics committees. This study does not involve patients
and hence written informed consent will not be
required.
DISCUSSION
BP lowering is one of the priority areas identiﬁed for
action by the WHF if the target of a 25% reduction in
premature CVD mortality by 2025 is to be achieved. This
research will allow the generation of evidence on the
presence of substandard antihypertensive medicines
among generic antihypertensive medicines in a develop-
ing country. This is anticipated to sensitise policymakers,
national drug regulatory authorities and governments to
the issue of substandard medicines and facilitate debate
among health providers, national cardiology societies/
associations and civil society representatives. Ultimately,
optimising antihypertensive medicine quality is likely to
reduce the overall cardiovascular burden in Nigeria.
This proposal ultimately aims to improve access to
good quality antihypertensive medicines in low-income
and middle-income countries and is therefore directly
linked to health service requirements needed to achieve
successful implementation of effective BP control. To
the best of our knowledge, no studies have been per-
formed in Nigeria (and other low-income and
middle-income countries) regarding the quality of the
available generic antihypertensive medicines. This pilot
study will (1) allow us to generate evidence on the
presence of substandard antihypertensive medicines
(based on the physicochemical equivalence) among
generic antihypertensive medicines in a low-income
and middle-income country; (2) help to sensitise the
policymakers, national drug regulatory authorities
and key regional and national governments; and
ﬁnally (3) allow a debate among health providers,
national cardiology societies/associations and civil
society representatives. Future research will be
needed to expand the sampling framework, including
branded medicines, more samples and more locations
in more countries.
For this research, we have limited the chosen areas of
Nigeria due to previous research related to substandard
antimalarial medicines and also for practical reasons.
However, it is important to acknowledge that this is a
small step aimed at catalysing debate related to the
quality of antihypertensive medicines available in devel-
oping countries. This pilot study is also limited by the
nature of the sampling framework (although rando-
mised); it will, however, inform future research and
optimal sampling as well as practical barriers and
enablers to this type of research. In addition, this
research is limited to generic medicines only and future
research should also include branded medicines. In this
initial research, we will not involve the national regulator
given their role and impact remains unclear. However,
the research team will liaise with and gain support of
local health ofﬁcials to ensure governance during
sample collection.
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